Aptinyx to Present at Upcoming Virtual Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that company
management will be presenting at the following virtual investor
- H.C. Wainwright 22nd Annual Global Investment Conference at
3:00 p.m. ET on Monday, September 14, 2020; and
- Cantor Virtual Global Healthcare Conference at 8:00 a.m. ET on
Thursday, September 17, 2020.
A live webcast of each presentation will be available on the
“Events and Presentations” page in the “Investors & Media”
section of Aptinyx’s website at https://ir.aptinyx.com. A replay of
the webcast will be archived on Aptinyx’s website for 30 days
following the event.
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment associated with Parkinson’s disease. Aptinyx is also
advancing additional compounds from its proprietary discovery
platform, which continues to generate a rich and diverse pipeline
of small-molecule NMDA receptor modulators with the potential to
treat an array of neurologic disorders. For more information, visit
Source: Aptinyx Inc.
version on businesswire.com: https://www.businesswire.com/news/home/20200903005303/en/
Investor and Media Contact: Nick Smith Aptinyx Inc.
firstname.lastname@example.org or email@example.com 847-871-0377